David Hassman

1.2k total citations
16 papers, 739 citations indexed

About

David Hassman is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pharmacology. According to data from OpenAlex, David Hassman has authored 16 papers receiving a total of 739 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Surgery and 3 papers in Pharmacology. Recurrent topics in David Hassman's work include Pain Management and Opioid Use (3 papers), Pediatric Pain Management Techniques (3 papers) and Hepatitis C virus research (3 papers). David Hassman is often cited by papers focused on Pain Management and Opioid Use (3 papers), Pediatric Pain Management Techniques (3 papers) and Hepatitis C virus research (3 papers). David Hassman collaborates with scholars based in United States, Denmark and Puerto Rico. David Hassman's co-authors include Naum Khutoryansky, Paula M. Hale, Elinor Miller, Harold Bays, James M. McKenney, Rohini Chitra, W. Virgil Brown, Howard G. Hutchinson, Julian Howell and Srinivas Nalamachu and has published in prestigious journals such as Diabetes Care, Journal of Hepatology and American Heart Journal.

In The Last Decade

David Hassman

16 papers receiving 681 citations

Peers

David Hassman
Annpey Pong United States
Steven Bird United States
Teun M. Post Netherlands
Johannes Mulder Netherlands
Bernard E. Ilson United States
Hilde Giezek United States
Rahul Shah United States
Jorge Contreras Spain
Jasmine A. Luzum United States
Nassim Djebli France
Annpey Pong United States
David Hassman
Citations per year, relative to David Hassman David Hassman (= 1×) peers Annpey Pong

Countries citing papers authored by David Hassman

Since Specialization
Citations

This map shows the geographic impact of David Hassman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hassman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hassman more than expected).

Fields of papers citing papers by David Hassman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hassman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hassman. The network helps show where David Hassman may publish in the future.

Co-authorship network of co-authors of David Hassman

This figure shows the co-authorship network connecting the top 25 collaborators of David Hassman. A scholar is included among the top collaborators of David Hassman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hassman. David Hassman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Learned, Susan M., et al.. (2023). 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies. Journal of Substance Use and Addiction Treatment. 154. 209155–209155. 7 indexed citations
2.
Andorn, Anne C., Barbara R. Haight, Sunita Shinde, et al.. (2020). Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis. Journal of Clinical Psychopharmacology. 40(3). 231–239. 31 indexed citations
3.
Davis, John D., Ashish Bansal, David Hassman, et al.. (2018). Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab. Clinical Pharmacology & Therapeutics. 104(6). 1146–1154. 34 indexed citations
4.
Rodríguez‐Torres, M., John M. Hill, B. Freilich, et al.. (2016). GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study. Journal of Viral Hepatitis. 23(8). 614–622. 40 indexed citations
5.
Rodríguez‐Torres, M., John M. Hill, B. Freilich, et al.. (2015). P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study. Journal of Hepatology. 62. S682–S682. 3 indexed citations
6.
Lawitz, Eric, Daniel Gruener, Thomas Marbury, et al.. (2014). Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C. Antiviral Therapy. 20(7). 699–708. 27 indexed citations
7.
Nalamachu, Srinivas, Richard Rauck, Mark S. Wallace, David Hassman, & Julian Howell. (2012). Successful Dose Finding with Sublingual Fentanyl Tablet: Combined Results from 2 Open‐Label Titration Studies. Pain Practice. 12(6). 449–456. 7 indexed citations
8.
Eshun‐Wilson, Ingrid, Christina Arce, Christopher R. Ellis, et al.. (2011). Evaluation of a new safety peripheral IV catheter designed to reduce mucocutaneous blood exposure. Current Medical Research and Opinion. 27(7). 1339–1346. 7 indexed citations
9.
Nalamachu, Srinivas, et al.. (2011). Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Current Medical Research and Opinion. 27(3). 519–530. 32 indexed citations
10.
Rauck, Richard, et al.. (2009). Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Current Medical Research and Opinion. 25(12). 2877–2885. 103 indexed citations
11.
Insull, William, Jalal K. Ghali, David Hassman, et al.. (2007). Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR Trial. Mayo Clinic Proceedings. 82(5). 543–550. 32 indexed citations
12.
13.
Bode, Bruce W., J J Shelmet, David Hassman, et al.. (2004). Patient Perception and Use of an Insulin Injector/Glucose Monitor Combined Device. The Diabetes Educator. 30(2). 301–308. 8 indexed citations
14.
Rosenstock, Julio, David Hassman, Shari A. Brazinsky, et al.. (2004). Repaglinide Versus Nateglinide Monotherapy. Diabetes Care. 27(6). 1265–1270. 137 indexed citations
15.
Jovanovič, Lois, et al.. (2003). Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Research and Clinical Practice. 63(2). 127–134. 60 indexed citations
16.
Brown, W. Virgil, Harold Bays, David Hassman, et al.. (2002). Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. American Heart Journal. 144(6). 1036–1043. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annpey Pong Breakdown of academic impact, for papers by Steven Bird Breakdown of academic impact, for papers by Teun M. Post Breakdown of academic impact, for papers by Johannes Mulder Breakdown of academic impact, for papers by Bernard E. Ilson Breakdown of academic impact, for papers by Hilde Giezek Breakdown of academic impact, for papers by Rahul Shah Breakdown of academic impact, for papers by Jorge Contreras Breakdown of academic impact, for papers by Jasmine A. Luzum Breakdown of academic impact, for papers by Nassim Djebli
Rankless by CCL
2026